Clinical Study
Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

Malgorzata Labuda,1 Sophie Laberge,2 Julie Brière,1 Denis Bérubé,2 Patrick Beaulieu,1 Tomi Pastinen,3 and Maja Krajinovic1,2,4

1 Research Center, CHU Sainte-Justine, Montreal, QC, Canada H3T 1C5
2 Department of Paediatrics, University of Montreal, Montreal, Qc, Canada H3T 1C5
3 Department of Human Genetics, McGill University and Génome Québec Innovation Centre, Montreal, Qc, Canada H3A 1A4
4 Department of Pharmacology, University of Montreal, Montreal, Qc, Canada H3T 1J4

Correspondence should be addressed to Maja Krajinovic, maja.krajinovic@umontreal.ca

Received 27 January 2011; Revised 16 June 2011; Accepted 1 July 2011

Academic Editor: E. Moilanen

Copyright © 2011 Malgorzata Labuda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Short-acting β2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. The aim of this study was to test whether genetic variants in PDE4D gene, a key regulator of β2-adrenoceptor-induced cAMP turnover in airway smooth muscle cells, affect the response to short-acting β2-agonists. Bronchodilator responsiveness was assessed in 133 asthmatic children by % change in baseline forced expiratory volume in one second (FEV1) after administration of albuterol. The analyses were performed in patients with airway obstruction (FEV1/FVC ratio below 90%, n = 93). FEV1 % change adjusted for baseline FEV1 values was significantly different between genotypes of rs1544791 G/A polymorphism (P = 0.006) and −1345 C/T (rs1504982) promoter variation (P = 0.03). The association remained significant with inclusion of age, sex, atopy, and controller medication into multivariate model (P = 0.004 and P = 0.02, resp.). Our work identifies new genetic variants implicated in modulation of asthma treatment, one of them (rs1544791) previously associated with asthma phenotype.

1. Introduction

Asthma (MIM 600807) is a common chronic respiratory disease resulting from the complex interaction of genetics and environmental factors [1]. Short-acting β2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. Activated β2-adrenergic receptor (ADRB2) stimulates adenyl cyclase leading to increased cyclic adenosine monophosphate (cAMP) level. A primary function of cAMP is to activate protein kinase A (PKA), which in turn activates myosin light chain phosphatase, reducing phosphorylation and generating relaxation [2]. cAMP-activated PKA also activates and phosphorylates phosphodiesterase 4 (PDE4) isoforms which then degrade cAMP providing thus a pivotal acute feedback mechanism [2–4].

PDE enzymes, ubiquitously distributed in mammalian tissues, are essential to control numerous physiological processes. PDEs are encoded by 11 gene families, each encompassing 1 to 4 subfamilies of distinct genes [5, 6]. The PDE4 family has gained interest in view of their involvement in the regulation of processes such as inflammation and cognition [3, 7]. Four genes (4A–D) encode a large number of PDE4 isoforms through activation of different promoters or alternative splicing [3, 7]. The dominant PDE4 type expressed in airway smooth muscle cells is PDE4D [8–10]. PDE4D encode a variety of long and short isoforms which are summarized in Figure 1. Long PDE4D5 isoform was shown to be a key regulator of β2-adrenoceptor-induced cAMP turnover in human airway smooth muscle cells [11]. The promoter of PDE4D5 isoform contains a cAMP response element [8]. Chronic elevation of cAMP
could therefore lead to desensitization of the receptor to b2-agonists following long-term exposure. This differs from the acute transient desensitization of the receptor caused by PKA phosphorylation and activation or by agonist-triggered b-arrestin-mediated recruitment to the b2-adrenoreceptor [12, 13]. Experiments using knockout mice for PDE4D gene further supported PDE4D role in a regulation of airway smooth muscles contractility [9, 14].

It is thus not surprising that recent genome-wide association study (GWAS) for asthma identified PDE4D as a highly plausible candidate gene [18]. PDE4D was also associated with mineral bone density [16], chronic obstructive pulmonary disease (COPD) [17], and stroke [15]. PDE4D associations with diverse phenotypes are most likely due to its multiple splicing forms with exons scattered over 1.5 Mb, each regulated in a tissue-and-cell specific manner and involved in multiple signalling processes [3, 7, 20].

As the role of PDE4 enzymes was discovered, the interest in controlling their activity was apparent, as summarized in several reviews [2, 20–23]. PDE4 inhibitors have been also viewed as a promising therapy for the treatment of inflammatory airway disorders [24]. The potentially beneficial action of PDE4 inhibitors has been successfully translated in clinical trials for COPD treatment [22, 25, 26], and their efficacy for asthma control is presently under investigation [27].

No data are yet available on the involvement of this gene in the response to drugs used in asthma treatment. The aim of this study was to test the genetic variants in PDE4D gene as potential predictive factor of the response to a single dose of short-acting b2-agonist.

2. Patients and Methods

2.1. Patients. Patients (n = 133) were recruited from the asthma and outpatient pulmonary clinics at Sainte-Justine Hospital between March 2007 and September 2010. Subjects were eligible if they were Caucasians, aged 5 to 18 years, able to perform an appropriate spirometric maneuver under the supervision of technicians specifically trained in pulmonary function testing of children [28], and meeting standard criteria for a diagnosis of asthma [29]. Subjects were eligible for the recruitment irrespectively of the type of maintenance therapy (inhaled corticosteroids, ICS, or leukotriene modifiers) and irrespectively of disease control and severity. Atopy was defined as presence of physician-diagnosed eczema and/or serum food-specific IgE and/or positive skin test for 1 or more aeroallergens or food antigens [30]. Exclusion criteria were as follows: use of long-acting bronchodilators in the last month, prematurity, a history of significant pulmonary disease other than asthma, and known immunodeficiencies. The study protocol was reviewed and approved by the Sainte-Justine Hospital Ethics Committee, and informed consent was signed by each patient’s parent.

To assess bronchodilator responsiveness, four inhalations of albuterol were administered via metered dose inhaler (100 μg/inhalation) with valved holding chamber and mouthpiece (Aerochamber; Invacare Corp, Elyria, Ohio, USA). Spirometry was performed before (pre) and 15 min after (post) receiving albuterol sulfate in accordance with the American Thoracic Society guidelines [28]. Short-acting bronchodilators were withheld 6 hours prior to baseline spirometry. Responsiveness to albuterol was reported as the percent change in forced expiratory volume in one second (FEV1) after albuterol administration: 100 × ((FEV1(post) – FEV1(pre))/(pre)). The equations proposed by Polgar and Promadath [31] were selected for the calculation of predicted and reference values.

2.2. Genotyping. DNA was extracted from saliva using Oragen kit according to manufacturer (DNA Genotek, http://www.dnagenotek.com). Four SNPs in PDE4D gene were selected for the analysis. Two polymorphisms, located at positions −1345 (rs1504982) and −984 (rs10940648) relative to the first nucleotide of PDE4D5 mRNA isoform (AF12073), were the only SNPs available at NCBI data base that reside in the 2 kb region preceding PDE4D5 transcription start site. Two other PDE4D polymorphisms were selected based on published data: rs1544791, located in the intron 2 of the
Table 1: Primers used for amplification and genotyping of PDE4D polymorphisms.

| SNP ID    | Position | PCR primers                                                | ASO primers                  |
|-----------|----------|------------------------------------------------------------|------------------------------|
| rs1544791 | Intron 2 | GAAGCATGTTGACATAAACAGT, TCTCTACTCTTATGGGGTTTCTG            | ATGTGGCA/GTTATTTGCA          |
| rs1504982 | −1345    | GGGAGCTAATAATGCAAT, CAAGTGTGGACCCTGTGC                     | ATTCCTTGCACTTTTTAAA          |
| rs10940648| −984     | CGTGTATTCCCTTTATTGGCTT, TTCCCTATGCAAAGGTGTGAG              | AGTAAAAAT/GGTTGAAC           |
| rs829259  | 3′ UTR   | TGTGCCGTAGGTAAGTCGAAA, CCGTTTCCAGGCTCTGATT                 | TCCCTACTA/ACTTATGAT          |

rs1544791 is located in intron 2 of PDE4D7 isoform; positions of rs1504982 and rs10940648 refer to the start of PDE4D5 mRNA (AF012073) and, rs829259 is located in 3′ UTR, common to all splice variants.

Table 2: Patients’ characteristics.

| Characteristic*               | Total (n = 133) | Total (n = 93) |
|-------------------------------|-----------------|----------------|
| Age, years                    | 9.8 (±0.3)      | 10.3 (±0.3)    |
| Males, n (%)                  | 73 (54.9)       | 55 (59.1)      |
| Females, n (%)                | 60 (45.1)       | 38 (40.9)      |
| Atopy**, n (%)                | 100 (75.2)      | 73 (78.5)      |
| Parental smoking, n (%)       | 36 (27.1)       | 27 (29.0)      |
| Regular ICS use, n (%)        | 68 (51.1)       | 48 (51.6)      |
| Leukotriene modifier use, n (%) | 28 (21.1)  | 21 (22.6)      |
| Baseline FVC, % predicted     | 106.8 (±1.1)    | 108.6 (±1.3)   |
| Baseline FEV₁, % predicted    | 96.9 (±1.2)     | 94.0 (±1.2)    |
| Baseline FEV₁/FVC ratio       | 84.5 (±0.8)     | 80.5 (±0.7)    |

*Patients’ characteristics are given as number (%) or mean ± SE for entire group of patients (n = 133) or for patients with FEV₁/FVC ratio below 90% (n = 93) to which the genotype analysis was restricted to; **presence of physician-diagnosed eczema, food-specific IGE, and/or positive skin test for 1 or more Aeroallergens or food allergens [30]; ICS: inhaled corticosteroids, FVC: forced vital capacity, FEV₁: forced expiratory volume in one second.

2.3. Statistical Analysis. The % change in FEV₁ was analyzed by analysis of covariance (ANCOVA). Genotype was included in the model as fixed factor, and the baseline FEV₁% predicted value was included as continuous covariate. The analyses were restricted to patients having airway obstruction, for example, baseline FEV₁/FVC (FVC: forced vital capacity) ratio lower than 90% [33, 34] (see Table 2 for patients characteristics). Hierarchical multivariate linear regression was used to assess the association between genotypes of rs1544791 and rs1504982 with the inclusion of additional covariates (age, sex, atopy, and use or not of ICS and leukotriene modifiers). The analyses were performed by SPSS (Version 17.0).

3. Results and Discussion

Details of patients’ characteristics are provided in Table 2. Asthma severity of patients recruited in our study is comparable to that observed in the Childhood Asthma Management Program (CAMP) and the Leukotriene Modifier or Corticosteroid or Corticosteroid Salmeterol trial (LOCCS) populations [35] used in a number of pharmacogenetic studies. Table 3 presents mean % FEV₁ change according to genotypes in PDE4D gene. Significant differences were obtained for PDE4D5 promoter −1345 (rs1504982, P = 0.03) and for rs1544791 polymorphisms (P = 0.006). The mean % FEV₁ change ± SE for rs1504982 C carriers was 7.1 ± 0.7 versus 10.3 ± 1.2 in noncarriers, and for rs1544791 G carriers, the mean % FEV₁ change ± SE was 7.4 ± 0.7 as compared to 13.7 ± 2.1 in individuals without this allele. The association remained significant for both SNPs with inclusion of age, sex, atopy, and controller medication into the multivariate model (P = 0.02 and P = 0.004, resp.).

The recent association of PDE4D to asthma phenotype [18], as well as its known function, makes PDE4D an excellent candidate gene for the association with the outcome of asthma treatment. PDE4D is a well-established regulator of airway smooth muscles contractility [9, 14] and plays a key role in ADRB2-induced cAMP regulation [11]. Study conducted in vitro demonstrated that a single nucleotide substitution in one of cAMP-responsive elements in PDE4D5 promoter created by site-directed mutagenesis, causes cAMP-driven upregulation of PDE4D5 expression and functional activity in human airway smooth muscle cells [8]. Based on the publicly available data, it does not seem that there is a naturally occurring genetic variant in PDE4D5 cAMP-responsive elements. Among SNPs analyzed here, −1345 variation of the PDE4D5 promoter was associated with the change in FEV₁ following a single dose of short-acting b2-agonist. The change in FEV₁ was also significantly associated with rs1544791, the top ranking SNP in GWAS study of asthma susceptibility [18]. The same G asthma...
values rather than categorical phenotype of responders and nonresponders based on a % FEV1 change above or below a given predefined value. The reason for this was a strong positive correlation between poor response to the administered albuterol and high baseline FEV1% predicted values. Since about 50% of our patients were on regular ICS and 20% were on leukotriene modifiers, it is reasonable to assume that prior treatment with these drugs had improved lung function in a proportion of our study subjects, therefore reducing the magnitude of the response to albuterol. Because of ethical considerations, we did not withdraw anti-inflammatory treatment prior to assessment, but we therefore restricted our analysis to the patients with airway obstruction. Since airway obstruction is defined by a reduced FEV1/FVC ratio [34] which normally reaches a value of 0.9 in children [33], we limited our analysis to patients with FEV1/FVC ratio lower than that threshold. An alternative strategy would have been to recruit new asthma patients prior to initiation of any asthma controller therapy. However, onset of childhood asthma usually occurs early during the preschool age and valuable spirometric data cannot be obtained in preschoolers. A multicenter study would have been necessary in order to recruit the appropriate numbers of patients.

4. Conclusions

This study demonstrates the first attempt to explore the association of PDE4D genetic variations and response to asthma b2-agonists treatment in Caucasian children. Results obtained are not necessarily applicable to other populations as frequency of tested polymorphisms and LD structure differ [18]. If confirmed in a larger study, this finding will build upon existing knowledge in asthma pharmacogenetics ultimately assisting personalized patient treatment.

Funding

The work was supported by a Grant from the Canadian Institutes of Health Research (MOP-81154); M. Krajinovic is a scholar of the Fonds de la Recherche en Santé du Québec. T. Pastinen is supported by CIHR and holds a CRC (tier 2).

Acknowledgments

The authors are thankful to all the patients and their parents who consented to participate in this study. They thank Dr. Chauhan Bhupendrasinh for the critical reading of the manuscript.

References

[1] S. T. Weiss, “Gene by environment interaction and asthma,” Clinical and Experimental Allergy, vol. 29, supplement 2, pp. 96–98, 1999.
[2] M. D. Houslay, “Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown,” Trends in Biochemical Sciences, vol. 35, no. 2, pp. 91–100, 2011.

Table 3: FEV1 % change following administration of albuterol according to PDE4D genotypes.

| SNP/genotypes | N | % FEV1 change (mean ± SE)** | P*** |
|---------------|---|----------------------------|------|
| rs1544791 intron 2 | | | |
| AA | 8 | 13.7 (±2.1) | 0.01 |
| AG | 34 | 6.6 (±1.0) | |
| GG | 51 | 7.9 (±0.8) | |
| GG + GA versus AA | 7.4 ± 0.7 versus 13.7 ± 2.1 | 0.006 |
| rs1504982 (−1345*) | | | |
| CC | 22 | 7.0 (±1.3) | |
| CT | 46 | 7.1 (±0.9) | 0.08 |
| TT | 25 | 10.3 (±1.2) | |
| CC + CT versus TT | 7.1 ± 0.7 versus 10.3 ± 1.2 | 0.03 |
| rs10940648 (−984*) | | | |
| CC | 6 | 8.2 (±2.6) | |
| TC | 28 | 6.6 (±1.2) | 0.4 |
| TT | 59 | 8.5 (±0.8) | |
| rs829259 | | | |
| AA | 13 | 8.5 (±1.7) | |
| AT | 45 | 6.6 (±0.9) | 0.1 |
| TT | 35 | 9.5 (±1.1) | |

rs1544791 is located in intron 2 of PDE4D7 isoform; *positions of rs1504982 and rs10940648 refer to the start of PDE4D5 mRNA (AF012073), and rs829259 is located in 3′UTR common to all splice variants; **mean values adjusted for baseline FEV1; ***P derived from ANCOVA.

Schematic representation of PDE4D gene structure and relation to PDE4D isoforms is given in Figure 1. SNPs tested within this study are depicted as well as those associated with variety of phenotypes reported by others [15–17]. Each of the phenotypes associated with PDE4D gene (stroke, asthma, BMD, and COPD) maps to different linkage disequilibrium (LD) blocks. The same is true for the SNPs significantly associated with b2-agonist response in this study. The SNP rs1544791 is located within 181 kb intron 2 of PDE4D7 (NM_001165899.1). This SNP resides within 75 kb long LD block and is separated by 374 kb from PDE4D5 transcription start. Despite its distant location, it could act as a remote cis-acting element. Indeed, functional-SNP database (F-SNP) integrating information from 16 bioinformatics tools [36] predicts that it might be a transcription regulator. We further assessed rs1544791 in allelic expression dataset generated in HapMap lymphoblastoid (CEU) cell lines of European ancestry [37] where allelic differences within individual were renormalized as recently described [38]. Population differences for allelic expression of uc010iwj.1 isoform (also corresponding to the first few exons unique to the longest PDE4D7 isoform NM_001165899.1 [7]) were significantly associated (P = 0.005) with rs1544791 genotype. SNP −1345 is also recognized as transcription regulator in F-SNP data base [36] and in UCSC browser (http://genome.ucsc.edu).

In the analysis, we used % FEV1 change as a continuous variable with the correction for baseline FEV1% predicted predisposing allele was associated in our study with the poor treatment outcome.
[3] M. D. Houslay and D. R. Adams, “PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling crosstalk, desensitization and compartmentalization,” Biochemical Journal, vol. 370, part 1, pp. 1–18, 2003.

[4] S. J. MacKenzie, G. S. Baillie, I. McPhee et al., “Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1),” British Journal of Pharmacology, vol. 136, no. 3, pp. 421–433, 2002.

[5] M. Conti and S. L. Jin, “The molecular biology of cyclic nucleotide phosphodiesterases,” Progress in Nucleic Acid Research and Molecular Biology, vol. 63, pp. 1–38, 1999.

[6] M. D. Houslay, “PDE4 cAMP-specific phosphodiesterases,” Progress in Nucleic Acid Research and Molecular Biology, vol. 69, pp. 249–315, 2001.

[7] M. D. Houslay, “The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target,” Molecular Pharmacology, vol. 68, no. 3, pp. 563–567, 2005.

[8] I. R. Le Jeune, M. Shepherd, G. van Hecke, M. D. Houslay and I. P. Hall, “Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4DS in human airway smooth muscle cells: identification and characterization of a novel PDE4DS promoter,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 35980–35989, 2002.

[9] C. Méhats, S. L. Jin, J. Wahlstrom, E. Law, D. T. Uematsu, and M. Conti, “PDE4D plays a critical role in the control of airway smooth muscle contraction,” FASEB Journal, vol. 17, no. 13, pp. 1831–1841, 2003.

[10] T. J. Torphy, B. J. Undem, L. B. Cieslinski, M. A. Luttmann, M. L. Reeves, and D. W. Hay, “Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle,” Journal of Pharmacology and Experimental Therapeutics, vol. 265, no. 3, pp. 1213–1223, 1993.

[11] C. K. Billington, I. R. Le Jeune, K. W. Young, and I. P. Hall, “A major functional role for phosphodiesterase 4DS in human airway smooth muscle cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 38, no. 1, pp. 1–7, 2008.

[12] G. S. Baillie, A. Sood, I. McPhee et al., “β-arrestin-mediated PDE4C4 phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 940–945, 2003.

[13] M. J. Lynch, G. S. Baillie, A. Mohamed et al., “RNA silencing identifies PDE4D5 as the functionally relevant CAMP phosphodiesterase interacting with farrestin to control the protein kinase A/ AKAP79-mediated switching of the β2-adrenergic receptor to activation of ERK in HEK293B2 cells,” Journal of Biological Chemistry, vol. 280, no. 39, pp. 33178–33189, 2005.

[14] G. Hansen, S. L. Jin, D. T. Uematsu, and M. Conti, “Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6751–6756, 2000.

[15] S. Gretarsdottir, G. Thorleifsson, S. T. Reynisdottir et al., “The gene encoding phosphodiesterase 4D confers risk of ischemic stroke,” Nature Genetics, vol. 35, no. 2, pp. 131–138, 2003.

[16] R. H. Reneland, S. Mah, S. Kammerer et al., “Association between a variation in the phosphodiesterase 4D gene and bone mineral density,” BMC Medical Genetics, vol. 6, article 9, 2005.

[17] S. Homma, T. Sakamoto, A. E. Hegab et al., “Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism,” International Journal of Molecular Medicine, vol. 18, no. 5, pp. 953–959, 2006.

[18] B. E. Himes, G. M. Hunninghake, J. W. Baurlcy et al., “Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene,” American Journal of Human Genetics, vol. 84, no. 5, pp. 581–593, 2009.

[19] A. Munshi and S. Kaul, “Stroke genetics—focus on PDE4D gene,” International Journal of Stroke, vol. 3, no. 3, pp. 188–192, 2008.

[20] M. D. Houslay, P. Schafer, and K. Y. Zhang, “Keynote review: phosphodiesterase-4 as a therapeutic target,” Drug Discovery Today, vol. 10, no. 22, pp. 1503–1519, 2005.

[21] R. E. Weishaar, M. H. Cain, and J. A. Bristol, “A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity,” Journal of Medicinal Chemistry, vol. 28, no. 5, pp. 537–545, 1985.

[22] D. Spina, “PDE4 inhibitors: current status,” British Journal of Pharmacology, vol. 155, no. 3, pp. 308–315, 2008.

[23] B. J. Lipworth, “Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease,” Lancet, vol. 365, no. 9545, pp. 167–175, 2005.

[24] R. W. Chapman, A. House, J. Richard et al., “Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration,” European Journal of Pharmacology, vol. 643, no. 2–3, pp. 274–281, 2010.

[25] J. Chong, P. Poole, R. Leung, and P. N. Black, “Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD002309, 2011.

[26] A. Hatzelmann, E. J. Morcillo, G. Lungarella et al., “The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease,” Pulmonary Pharmacology and Theraeutics, vol. 23, no. 4, pp. 235–256, 2010.

[27] A. T. Niels, C. J. Traal-Stewart, M. H. Gascoigne, D. I. Ball, L. E. Ranshaw, and R. G. Knowles, “In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 137–144, 2011.

[28] M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation of spirometry,” European Respiratory Journal, vol. 26, no. 2, pp. 319–328, 2005.

[29] National Asthma Education and Prevention Program, “Expert Panel report 3: guidelines for the diagnosis and management of asthma,” U.S. Department of Health and Humane Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.

[30] L. B. Bacharier, A. Boner, K. H. Carlsen et al., “Definition and treatment of asthma in childhood: a PRACTALL consensus report,” Allergy, vol. 63, no. 1, pp. 5–34, 2008.

[31] G. Polgar and V. Promadath, Pulmonary Function Testing in Children: Techniques and Standards, WB Saunders, Philadelphia, Pa, USA, 1974.

[32] S. Bourgeois and D. Labuda, “Dynamic allele-specific oligonucleotide hybridization on solid support,” Analytical Biochemistry, vol. 324, no. 2, pp. 309–311, 2004.

[33] M. D. Lougheed, C. L. Lemiere, S. D. Dell et al., “Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada,” Canadian Respiratory Journal, vol. 17, no. 1, pp. 15–24, 2010.

[34] R. Pellegrino, G. Viegi, V. Brusasco et al., “Interpretative strategies for lung function tests,” European Respiratory Journal, vol. 26, no. 5, pp. 948–968, 2005.

[35] A. A. Litonjua, J. Lasky-Su, K. Schneider et al., “ARG1 is a novel bronchodilator response gene: screening and replication in
four asthma cohorts,” *American Journal of Respiratory and Critical Care Medicine*, vol. 178, no. 7, pp. 688–694, 2008.

[36] P. H. Lee and H. Shatkay, “F-SNP: computationally predicted functional SNPs for disease association studies,” *Nucleic Acids Research*, vol. 36, no. 1, pp. D820–D824, 2008.

[37] B. Ge, D. K. Pokholok, T. Kwan et al., “Global patterns of cis variation in human cells revealed by high-density allelic expression analysis,” *Nature Genetics*, vol. 41, no. 11, pp. 1216–1222, 2009.

[38] E. Grundberg, V. Adoue, T. Kwan et al., “Global analysis of the impact of environmental perturbation on cis-regulation of gene expression,” *PLoS Genetics*, vol. 7, no. 1, Article ID e1001279, 2011.